Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Diabetes type 2, detectable C-peptide, HbA1c 7-10%~2. Pretreatment with basal insulin +/- Metformin or/and +/- Pioglitazone 3 Age \> 18 years, BMI \<= 45 kg/m2~Exclusion criteria:~1. Uncontrolled hyperglycemia during Run-in~2. Myocardial infarction, stroke or TIA within 3 months prior to informed consent~3. Liver impairment; gastric surgery; medical history of cancer in last 5 years~4. Other antidiabetic drugs, antiobesity drugs, systemic steroids, other investigational drug before randomisation~5. Unsufficient birth control, pregnancy and nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: EXPERIMENTAL): patient receives a tablet with intended final marketed dose
- Placebo (Type: PLACEBO_COMPARATOR): patient receives a tablet identical to those containing Linagliptin

Based on this trial design, predict the completion outcome and termination type (if applicable).